NCT03875859View on ClinicalTrials.gov

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

May 14, 2020

Study Completion Date

January 30, 2021

Conditions
Squamous Cell Carcinoma
Interventions
DRUG

Remetinostat

Topical 1% remetinostat gel

Trial Locations (1)

94304

Stanford Medical Center, Stanford

Sponsors

Collaborators (1)

Medivir
All Listed Sponsors
collaborator

Medivir

INDUSTRY

lead

Kavita Sarin

OTHER

NCT03875859 - Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC) | Biotech Hunter | Biotech Hunter